Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
This article was originally published in The Pink Sheet Daily
Executive Summary
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
You may also be interested in...
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.
With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor
Takeda/Millennium’s oral weekly proteasome inhibitor MLN9708 looked effective with a mild neuropathy profile in a new myeloma study presented at the American Society of Hematology meeting, and Takeda has committed to large Phase III trials. There’s no time to lose – mid-stage studies presented for Onyx’ rival Kyprolis, currently approved for relapsed myeloma, support moving that drug to the frontline.